GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Cyclically Adjusted PB Ratio

ONCY (Oncolytics Biotech) Cyclically Adjusted PB Ratio : 0.64 (As of May. 29, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Oncolytics Biotech's current share price is $0.3644. Oncolytics Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $0.57. Oncolytics Biotech's Cyclically Adjusted PB Ratio for today is 0.64.

The historical rank and industry rank for Oncolytics Biotech's Cyclically Adjusted PB Ratio or its related term are showing as below:

ONCY' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.64
Current: 0.64

During the past years, Oncolytics Biotech's highest Cyclically Adjusted PB Ratio was 0.64. The lowest was 0.00. And the median was 0.00.

ONCY's Cyclically Adjusted PB Ratio is ranked better than
65.82% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs ONCY: 0.64

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oncolytics Biotech's adjusted book value per share data for the three months ended in Mar. 2025 was $0.052. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.57 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Oncolytics Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Oncolytics Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Cyclically Adjusted PB Ratio Chart

Oncolytics Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 1.04 1.57 1.69 1.51

Oncolytics Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.39 1.29 1.51 0.97

Competitive Comparison of Oncolytics Biotech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Oncolytics Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Cyclically Adjusted PB Ratio falls into.


;
;

Oncolytics Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Oncolytics Biotech's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.3644/0.57
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Oncolytics Biotech's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.052/129.1809*129.1809
=0.052

Current CPI (Mar. 2025) = 129.1809.

Oncolytics Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201506 1.967 100.500 2.528
201509 1.683 100.421 2.165
201512 1.447 99.947 1.870
201603 1.239 101.054 1.584
201606 1.152 102.002 1.459
201609 0.937 101.765 1.189
201612 0.628 101.449 0.800
201703 0.426 102.634 0.536
201706 0.732 103.029 0.918
201709 0.664 103.345 0.830
201712 0.435 103.345 0.544
201803 0.245 105.004 0.301
201806 0.506 105.557 0.619
201809 0.410 105.636 0.501
201812 0.265 105.399 0.325
201903 0.224 106.979 0.270
201906 0.140 107.690 0.168
201909 0.104 107.611 0.125
201912 -0.003 107.769 -0.004
202003 0.444 107.927 0.531
202006 0.434 108.401 0.517
202009 0.374 108.164 0.447
202012 0.419 108.559 0.499
202103 0.673 110.298 0.788
202106 0.692 111.720 0.800
202109 0.613 112.905 0.701
202112 0.512 113.774 0.581
202203 0.481 117.646 0.528
202206 0.415 120.806 0.444
202209 0.363 120.648 0.389
202212 0.318 120.964 0.340
202303 0.294 122.702 0.310
202306 0.255 124.203 0.265
202309 0.292 125.230 0.301
202312 0.276 125.072 0.285
202403 0.225 126.258 0.230
202406 0.174 127.522 0.176
202409 0.087 127.285 0.088
202412 0.052 127.364 0.053
202503 0.052 129.181 0.052

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oncolytics Biotech  (NAS:ONCY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Oncolytics Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.